The FDA has approved lumateperone (Caplyta) as an adjunctive therapy with antidepressants for treating major depressive disorder (MDD) in adults, according to Johnson & Johnson. The drug was already approved for use as both adjunctive therapy and monotherapy in bipolar I and II depression , as well as for the treatment of schizophrenia in adults.

MDD, or clinical depression, is one of the most common psychiatric disorders , affecting about 22 million American adults.4,5 While oral antidepressants may offer relief for some, 2 in 3 people living with MDD continue to experience residual symptoms despite treatment, significantly impacting their overall quality of life.6 Beyond its toll on patients’ wellbeing, MDD has a substantial economic burden and is the leading cause of disabi

See Full Page